Plasma calcitonin gene–related peptide and nerve growth factor as headache and pain biomarkers in recently deployed soldiers with and without a recent concussion
Headache: The Journal of Head and Face Pain · 2023-10 · 63 (9) · 1240-1250
DOI: 10.1111/head.14635 ↗Kurz gefasst
Fachartikel in der Zeitschrift Headache: The Journal of Head and Face Pain, online erschienen am 05.10.2023. Verfasst von Ann I Scher und 10 weiteren Autor:innen. Beteiligte Einrichtung: Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Military Personnel, Post-Traumatic Headache, Brain Concussion, Brain Injuries, Traumatic. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Center for Neuroscience and Regenerative Medicine, Congressionally Directed Medical Research Programs, Eli Lilly and Company.
Abstract (Originalsprache)
Objective
The objective of this study was to characterize the utility of calcitonin gene–related peptide (CGRP) and nerve growth factor (NGF) as potential biomarkers for headache and pain disorders in the post–military deployment setting.
Background
The need to improve recognition, assessment, and prognoses of individuals with posttraumatic headache or other pain has increased interest in the potential of CGRP and NGF as biomarkers.
Methods
The Warrior Strong Study (NCT01847040) is an observational longitudinal study of United States–based soldiers who had recently returned from deployment to Afghanistan or Iraq from 2009 to 2014. The present nested cross‐sectional analysis uses baseline data collected from soldiers returning to Fort Bragg, North Carolina.
Results
In total, 264 soldiers (mean (standard deviation [SD] age 28.1 [6.4] years, 230/264 [87.1%] men, 171/263 [65.0%] White) were analyzed. Mean (SD) plasma levels of CGRP were 1.3 (1.1) pg/mL and mean levels of NGF were 1.4 (0.4) pg/mL. Age was negatively correlated with NGF (−0.01 pg/mL per year, p = 0.007) but was not associated with CGRP. Men had higher mean (SD) CGRP plasma levels than women (1.4 95% confidence interval [CI; 1.2] vs. 0.9 95% CI [0.5] pg/mL, p < 0.002, Kruskal–Wallis test). CGRP levels were lower in participants who had a headache at the time of the blood draw (1.0 [0.6] pg/mL vs. 1.4 [1.2] pg/mL, p = 0.024). NGF was lower in participants with continuous pain (all types; 1.2 [0.4] vs. 1.4 [0.4] pg/mL, p = 0.027) and was lower in participants with traumatic brain injury (TBI) + posttraumatic headache (PTH) versus TBI without PTH (1.3 [0.3] vs. 1.4 [0.4] pg/mL, p = 0.021). Otherwise, CGRP and NGF were not associated with migraine‐like headache, TBI status, or headache burden as measured by the number of medical encounters in crude or adjusted models.
Conclusion
In this exploratory study, plasma levels of NGF and CGRP showed promise as biomarkers for headache and other types of pain. These findings need to be replicated in other cohorts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
- Vector Psychometric Group, Chapel Hill, North Carolina, USA.
- Pain Research, Eli Lilly and Company, Indianapolis, Indiana, USA.
- Precision Medicine Neuroscience, AbbVie, Chicago, Illinois, USA.
- US Public Health Service Commissioned Corps, Fayetteville, North Carolina, USA.
- Womack Army Medical Center, Fort Bragg, North Carolina, USA.
ORCID-Profile: Alan G Finkel
Förderung
- Center for Neuroscience and Regenerative Medicine
- Congressionally Directed Medical Research Programs
- Eli Lilly and Company
Zitieren
APA
Scher, A. I., McGinley, J. S., VanDam, L. R., Campbell, A. M., Chai, X., Collins, B., Klimp, S. A., Finkel, A. G., Schwab, K., Lipton, R. B., & Johnson, K. W. (2023). Plasma calcitonin gene–related peptide and nerve growth factor as headache and pain biomarkers in recently deployed soldiers with and without a recent concussion. Headache: The Journal of Head and Face Pain, 63(9), 1240-1250. https://doi.org/10.1111/head.14635
Vancouver
Scher AI, McGinley JS, VanDam LR, Campbell AM, Chai X, Collins B, et al. Plasma calcitonin gene–related peptide and nerve growth factor as headache and pain biomarkers in recently deployed soldiers with and without a recent concussion. Headache: The Journal of Head and Face Pain. 2023;63(9):1240-1250. doi:10.1111/head.14635
BibTeX
@article{Scher2023,
author = {Scher, Ann I and McGinley, James S and VanDam, Lyndsey R and Campbell, Amanda M and Chai, Xiyun and Collins, Billy and Klimp, Scott A and Finkel, Alan G and Schwab, Karen and Lipton, Richard B and Johnson, Kirk W},
title = {Plasma calcitonin gene–related peptide and nerve growth factor as headache and pain biomarkers in recently deployed soldiers with and without a recent concussion},
journal = {Headache: The Journal of Head and Face Pain},
year = {2023},
volume = {63},
number = {9},
pages = {1240--1250},
doi = {10.1111/head.14635}
}
EUVIMED